Digital therapeutics startup Respiree has received the United States Food and Drug Administration’s 510(k) clearance for its RS001 cardio-respiratory wearable.
It is part of the hospital’s smart remote health monitoring system project with A*STAR spinoff Respiree.
The device could save up to 12 man-hours daily, allowing nurses to focus on other aspects of a patient’s well-being.
Changi General Hospital partners Respiree to advance patient care through smart remote monitoring of vital signs: Potential for wearable medical sensor to maximise and improve productivity gains
Respiree Pte Ltd made it through the first round and has been selected as a Finalist for Falling Walls Venture 2022
Digital health startup Respiree has raised S$4.7 million in Series Seed equity funding led by Oriza Greenwillow Technology Fund, SEEDS capital and high-net-worth investors that include the she1K angel syndicate.
Amidst this pandemic, Singapore continues to invest in science and innovation, as well as grow a strong pool of talented scientists – some of whom contribute to the fight against Covid-19 using AI analytics.
Dedicated to research and innovation for the public good, the Agency for Science, Technology and Research (A*STAR) interviews 2 of their scholars; Dr Sarah Luo, Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), and Dr Gurpreet Singh, Senior Research Scientist at the Institute of Bioengineering and Bioimaging (IBB) and founder of Respiree Pte Ltd.
For Professor Patrick Cozzone, Executive Director of the Singapore Bioimaging Consortium and cofounder of Respiree, bioimaging lies at the heart of understanding fundamental biological processes.
Local medical technology startup Respiree’s wearable device which is used to measure vital parameters such as respiratory rate or blood oxygen levels.